NYSE:CRL (USA) Also trade in: Germany

Charles River Laboratories International Inc

$ 128.44 0 (0%)
Volume: 203,254 Avg Vol (1m): 388,196
Market Cap $: 6.26 Bil Enterprise Value $: 7.71 Bil
P/E (TTM): 27.94 P/B: 4.49
Earnings Power Value 13.73
Net Current Asset Value -33.61
Tangible Book -8.95
Projected FCF 91.56
Median P/S Value 107.38
Graham Number 0
Peter Lynch Value 72.27
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.08
Cash-To-Debt ranked lower than
88.51% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
CRL: 0.08
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 0.26, Max: 15.68
Current: 0.08
0.04
15.68
Equity-to-Asset 0.36
Equity-to-Asset ranked lower than
81.59% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
CRL: 0.36
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.28, Med: 0.4, Max: 0.72
Current: 0.36
-0.28
0.72
Debt-to-Equity 1.12
Debt-to-Equity ranked lower than
83.54% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
CRL: 1.12
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -3.68, Med: 0.7, Max: 1.8
Current: 1.12
-3.68
1.8
Debt-to-EBITDA 3.01
Debt-to-EBITDA ranked lower than
61.21% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
CRL: 3.01
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -3.42, Med: 2.71, Max: 3.29
Current: 3.01
-3.42
3.29
Interest Coverage 5.33
Interest Coverage ranked lower than
68.71% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
CRL: 5.33
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 3.62, Med: 7.52, Max: 14.87
Current: 5.33
3.62
14.87
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.53
DISTRESS
GREY
SAFE
Beneish M-Score -2.51
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 10.07%
WACC 7.82%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.03
Operating Margin ranked higher than
82.64% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
CRL: 14.03
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 11.28, Med: 14.55, Max: 15.91
Current: 14.03
11.28
15.91
Net Margin % 9.63
Net Margin ranked higher than
71.37% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
CRL: 9.63
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -29.7, Med: 9.4, Max: 10.95
Current: 9.63
-29.7
10.95
ROE % 18.19
ROE ranked higher than
79.75% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
CRL: 18.19
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -32.64, Med: 17.68, Max: 21.25
Current: 18.19
-32.64
21.25
ROA % 6.20
ROA ranked higher than
68.70% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
CRL: 6.2
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -17.1, Med: 6.44, Max: 7.58
Current: 6.2
-17.1
7.58
ROC (Joel Greenblatt) % 35.21
ROC (Joel Greenblatt) ranked higher than
76.83% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
CRL: 35.21
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -32, Med: 22.24, Max: 38.57
Current: 35.21
-32
38.57
3-Year Total Revenue Growth Rate 18.50
3-Year Revenue Growth Rate ranked higher than
64.84% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
CRL: 17.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -17.6, Med: 7.05, Max: 17.3
Current: 17.3
-17.6
17.3
3-Year Total EBITDA Growth Rate 18.40
3-Year EBITDA Growth Rate ranked higher than
62.92% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
CRL: 17.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 6.2, Max: 17.3
Current: 17.3
0
17.3
3-Year EPS w/o NRI Growth Rate 13.40
3-Year EPS w/o NRI Growth Rate ranked lower than
66.87% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
CRL: 13.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 4.7, Max: 27.3
Current: 13.4
0
27.3

» CRL's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CRL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 541714    SIC : 8732
Compare NAS:ICLR NAS:PRAH XPAR:ERF NAS:BRKR NAS:GH MIL:DIA NYSE:QGEN NAS:SYNH NYSE:BIO XPAR:BIM SZSE:300676 SHSE:603658 NYSE:PKI NAS:NEOG NAS:DXCM NAS:QDEL NAS:GHDX NAS:MYGN BSP:DASA3 XTER:SRT3
Traded in other countries RV6.Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Ratios

Current vs industry vs history
PE Ratio (TTM) 27.70
PE Ratio ranked lower than
66.37% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
CRL: 27.7
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 8.58, Med: 24.95, Max: 95.66
Current: 27.7
8.58
95.66
Forward PE Ratio 19.88
Forward P/E ranked higher than
75.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
CRL: 19.88
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 27.94
PE without NRI ranked lower than
65.49% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
CRL: 27.94
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 8.51, Med: 24.81, Max: 77.86
Current: 27.94
8.51
77.86
Price-to-Owner-Earnings 22.13
Price-to-Owner-Earnings ranked higher than
69.74% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
CRL: 22.13
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.56, Med: 20.72, Max: 323.25
Current: 22.13
10.56
323.25
PB Ratio 4.49
PB Ratio ranked lower than
57.14% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
CRL: 4.49
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.75, Med: 3.71, Max: 6.01
Current: 4.49
0.75
6.01
PS Ratio 2.67
PS Ratio ranked higher than
60.43% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
CRL: 2.67
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.12, Med: 2.22, Max: 3.64
Current: 2.67
1.12
3.64
Price-to-Free-Cash-Flow 23.64
Price-to-Free-Cash-Flow ranked higher than
61.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
CRL: 23.64
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.56, Med: 16.85, Max: 64.27
Current: 23.64
8.56
64.27
Price-to-Operating-Cash-Flow 15.91
Price-to-Operating-Cash-Flow ranked higher than
63.92% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
CRL: 15.91
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.82, Med: 12.16, Max: 18.14
Current: 15.91
4.82
18.14
EV-to-EBIT 22.20
EV-to-EBIT ranked higher than
66.95% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
CRL: 22.2
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -10.7, Med: 18.7, Max: 27.8
Current: 22.2
-10.7
27.8
EV-to-EBITDA 14.79
EV-to-EBITDA ranked higher than
71.21% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
CRL: 14.79
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -16.5, Med: 12.55, Max: 17.1
Current: 14.79
-16.5
17.1
EV-to-Revenue 3.27
EV-to-Revenue ranked higher than
57.44% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
CRL: 3.27
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.4, Med: 2.7, Max: 3.9
Current: 3.27
1.4
3.9
PEG Ratio 1.86
PEG Ratio ranked lower than
52.08% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
CRL: 1.86
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1.54, Med: 2.71, Max: 7.4
Current: 1.86
1.54
7.4
Shiller PE Ratio 62.96
Shiller PE Ratio ranked lower than
97.44% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
CRL: 62.96
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 56.57, Med: 162.33, Max: 1552.4
Current: 62.96
56.57
1552.4
Current Ratio 1.64
Current Ratio ranked lower than
66.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
CRL: 1.64
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.21, Med: 1.97, Max: 3.49
Current: 1.64
1.21
3.49
Quick Ratio 1.39
Quick Ratio ranked lower than
65.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
CRL: 1.39
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.95, Med: 1.65, Max: 3.02
Current: 1.39
0.95
3.02
Days Inventory 30.35
Days Inventory ranked higher than
72.55% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
CRL: 30.35
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 30.35, Med: 41.1, Max: 49.49
Current: 30.35
30.35
49.49
Days Sales Outstanding 57.57
Days Sales Outstanding ranked higher than
51.96% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
CRL: 57.57
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 49.63, Med: 59.17, Max: 65.57
Current: 57.57
49.63
65.57
Days Payable 19.03
Days Payable ranked lower than
87.70% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
CRL: 19.03
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 14.93, Med: 15.77, Max: 24.56
Current: 19.03
14.93
24.56

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.00
3-Year Share Buyback Rate ranked lower than
100.00% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
CRL: -1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -62.6, Med: 0.05, Max: 10.3
Current: -1
-62.6
10.3

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.40
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
76.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
CRL: 1.4
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.94, Med: 1.34, Max: 1.94
Current: 1.4
0.94
1.94
Price-to-Median-PS-Value 1.20
Price-to-Median-PS-Value ranked lower than
64.77% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
CRL: 1.2
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.55, Med: 1.22, Max: 1.85
Current: 1.2
0.55
1.85
Price-to-Peter-Lynch-Fair-Value 1.78
Price-to-Peter-Lynch-Fair-Value ranked lower than
76.67% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
CRL: 1.78
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.59, Med: 2.52, Max: 4.02
Current: 1.78
1.59
4.02
Earnings Yield (Joel Greenblatt) % 4.50
Earnings Yield (Greenblatt) ranked higher than
85.28% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
CRL: 4.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -24.3, Med: 5, Max: 14.4
Current: 4.5
-24.3
14.4
Forward Rate of Return (Yacktman) % 19.48
Forward Rate of Return ranked higher than
80.00% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
CRL: 19.48
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 2.8, Med: 5.6, Max: 20.2
Current: 19.48
2.8
20.2

More Statistics

Revenue (TTM) (Mil) $ 2,376.7
EPS (TTM) $ 4.64
Beta 1.09
Volatility % 31.62
52-Week Range $ 103 - 149.07
Shares Outstanding (Mil) 48.75

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y